T cells engineered to express single-chain antibody receptors that incorporate TCR-z and cluster designation (CD)28 signaling domains (scFv-a-erbB2-CD28-z) can be redirected in vivo to cancer cells that lack triggering costimulatory molecules. To assess the contribution of CD28 signaling to the function of the scFv-CD28-z receptor, we expressed a series of mutated scFv-CD28-z receptors directed against erbB2. Residues known to be critical for CD28 signaling were mutated from tyrosine to phenylalanine at position 170 or proline to alanine at positions 187 and 190. Primary mouse T cells expressing either of the mutant receptors demonstrated impaired cytokine (IFN-g and GM-CSF) production and decreased proliferation after antigen ligation in vitro and decreased antitumor efficacy in vivo compared with T cells expressing the wild-type scFv-CD28-z receptor, suggesting a key signaling role for the CD28 component of the scFv-CD28-z receptor. Importantly, cell surface expression, binding capacity and cytolytic activity mediated by the scFv-CD28-z receptor were not diminished by either mutation. Overall, this study has definitively demonstrated a functional role for the CD28 component of the scFv-CD28-z receptor and has shown that incorporation of costimulatory activity in chimeric scFv receptors is a powerful approach for improving adoptive cancer immunotherapy.
A doptive immunotherapy involving the ex vivo genetic modification of tumor-reactive immune effector cells and their reinfusion into cancer patients has recently gained much attention. Although current immunotherapies involving the adoptive transfer of lymphokineactivated killer (LAK) cells and tumor infiltrating lymphocytes (TILs), [1] [2] [3] or antigen-specific T-cell clones, [4] [5] [6] have demonstrated promise in the clinic against melanoma and/or renal cell carcinoma, the broad application of these therapies has been hampered due to difficulty in isolating and expanding such effector populations for all tumor types and toxicity associated with high-dose IL-2 coadministration. [7] [8] [9] In addition, the effectiveness of LAK cell and TIL therapy, and other approaches such as vaccination, has been restricted by downregulation of MHC-peptide molecules and/or lack of costimulatory ligands such as CD80 and CD86 on most tumors. 10, 11 An approach to overcome these limitations has involved the engraftment of T cells with surfacebound single-chain (scFv) chimeric receptors reactive with tumor-associated antigens (TAA). Indeed, engineered T lymphocytes expressing scFv chimeric receptors have demonstrated antigen-specific binding, target cell lysis and antitumor efficacy in vivo. [12] [13] [14] [15] [16] [17] This approach offers a number of advantages over other immunotherapeutic approaches including (i) no requirement for MHC restriction and therefore no potential for tumor escape by MHC/peptide loss, (ii) an abundance of T cells reactive with the cancer and (iii) a variety of candidate TAA expressed on a broad spectrum of tumors and available as targets for gene-engineered T cells.
Initial chimeric receptor designs comprising TCR-z or FceRI-g cytoplasmic signaling domains (scFv-z or scFv-g, respectively) have both been reported to mediate target cell lysis in vitro and in vivo effectively. 14, 15, [18] [19] [20] Previous studies have also demonstrated that mutation of a critical tyrosine residue within the ITAM of either the TCR-z or FcR-g cytoplasmic signaling chains abrogated cytolytic function by these chimeric receptors. 14, 21 Although our recent study has demonstrated more effective control of tumor growth in vivo by T cells expressing scFv receptors containing the TCR-z chain, 16 scFv receptors containing either TCR-z or FceRI-g signaling tails alone have not been demonstrated to control effectively the growth of established tumors or metastatic disease. 22, 23 Given that T cells require both a primary TCR-mediated signal and a secondary costimulatory signal for optimal activation and function and that tumors often lack important costimulatory ligands such as CD80 or CD86, an scFv receptor incorporating both TCR-z and CD28 signaling domains into its cytoplasmic tail (scFv-CD28-z) was generated. Human and mouse T cells engineered with the scFv-CD28-z receptor have demonstrated enhanced cytokine secretion and proliferation in vitro, [23] [24] [25] and more recently enhanced antitumor efficacy in vivo when compared to T cells expressing the scFv-z receptor. 22, 23 Importantly, T cells expressing the scFv-CD28-z receptor were able to mediate responses effectively against tumors that lacked CD28 ligands.
Although scFv-CD28-z-modified T cells were demonstrated to have enhanced therapeutic efficacy, these studies had not proven whether the CD28 component of the receptor primarily functioned as a spacer domain to enhance TCR-z-mediated signaling or provided its own activity to gene-engineered T cells. To determine whether the latter was true, mutant scFv receptors were expressed in primary mouse T cells by retroviral transduction, including those containing mutations within the cytoplasmic PXXP or YMNM signaling motifs of CD28, known to be critical for CD28 signal transduction. [26] [27] [28] In this study, mouse T lymphocytes expressing the scFv-CD28-(P187/190)-z or scFv-CD28-(Y170F)-z mutant receptors demonstrated reduced proliferation and a significant reduction in both IFN-g and GM-CSF secretion after antigen ligation in vitro. Consistent with an important role for IFN-g in vivo, such T cells demonstrated a decreased ability to eradicate tumor in vivo compared to T cells expressing the wild-type scFv-CD28-z receptor. These data have clearly demonstrated for the first time a critical contribution of CD28 within the scFv-CD28-z receptor and demonstrates that fusing signaling domains can be a powerful approach for designing chimeric receptors that enhance adoptive T cell therapy.
Methods
Cell culture MEL 624.38 human melanoma cells, 24JK mouse C57BL/6 (B6) sarcoma cells (kindly provided by Dr Patrick Hwu, NIH, Betheseda, MD), MC38 mouse B6 colon adenocarcinoma cells and the erbB2-expressing MC38-erbB2 cells were cultured in RPMI 1640 or DMEM supplemented with 10% (v/v) FCS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies, Grand Island, NY). All tumor cell lines used were negative for the costimulatory ligands CD80 and CD86. GP þ E86 and PA317 retroviral packaging cells were maintained in supplemented DMEM. Retrovirus-producing GP þ E86 cells were cultured in DMEM containing 0.5 mg/ml G418 (Life Technologies). Transduced T cells were cultured in DMEM with 100 U/ml of human rIL-2 (kindly provided by Chiron, Emeryville, CA). 
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Chimeric receptor gene construction and site-directed mutagenesis
A chimeric gene construct composed of the scFv-antierbB2 monoclonal antibody (mAb), a membrane proximal hinge region of human CD8, and the transmembrane and cytoplasmic regions of the mouse CD28 signaling chain fused to the cytoplasmic region of mouse TCR-z (scFv-anti-erbB2-CD28-z) was cloned into the retroviral vector pLXSN (a kind gift from Dusty Miller, Fred Hutchinson Cancer Research Centre, Seattle, WA), as previously described. 23 The chimeric receptor contained a c-myc tag epitope at the C terminus of the variable light chain (V L ) region for detection in primary mouse T cells. Amino acid residues at positions P187, P190 and Y170 of the cytoplasmic CD28 domain were subjected to sitedirected mutagenesis using the Stratagene QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). The wild-type scFv-anti-erbB2-CD28-z cDNA construct was used as a template in the following PCR reactions. Primers designated sense -5 0 -GCCTTACCAGG-CCTACGCCGCTGCCAGAGAC-3 0 and antisense-5 0 -CGGAATGGTCCGGATGCGGCGACGGTCTCTG-3 0 were used for the P187/190A mutagenesis reaction to generate the scFv-CD28-(P187/190A)-z mutant construct and sense -5 0 -GAACAGACTCCTTCAAAGTGACTT-CATGAACATGACTC-3 0 and antisense-5 0 -CTTGTCT-GAGGAAGTTTCACTGAAGTACTTGTACTGAG-3 0 were used for the Y170F mutagenesis reaction to generate the scFv-CD28-(Y170F)-z mutant construct. Mutations were verified by automated sequence analysis.
Retroviral transduction of mouse primary T lymphocytes
GP þ E86 packaging cell lines stably expressing the scFv-anti-erbB2-CD28-z, -CD28-(P187/190A)-z or -CD28-(Y170F)-z receptors were isolated as described previously. 15, 16 Transduction of mouse spleen T lymphocytes was performed using GP þ E86 clones producing B10 7 cfu/ml. Prior to transduction, spleen cells from BALB/c mice were depleted of red blood cells (RBC) by hypotonic lysis with NH 4 Cl and enriched using a nylon wool syringe as described. 15, 16 Enriched mouse T cells (10 7 ) were then cocultivated with 5 Â 10 5 viral producing packaging cells in DMEM for 72 hours together with 4 mg/ml polybrene, 5 mg/ml PHA (Sigma, St Louis, MO) and 100 U/ml rIL-2. After cocultivation, transduction efficiency of mouse T cells was analyzed by flow cytometry.
Flow cytometry
Mouse T lymphocytes were stained for chimeric receptor expression with a primary anti-c-myc tag Ab (Cell Signaling Technology, MA), followed by staining with a PE-labeled anti-mouse Ig mAb (Becton Dickinson, San Jose, CA). Background fluorescence was analyzed using the PE-labeled anti-mouse Ig mAb alone. Cell surface phenotyping of transduced cells was determined by direct staining with FITC-labeled anti-CD4 (H129.19, Sigma) and Quantum-red-labeled anti-CD8 (R-3762, Sigma) mAbs, as previously described. 15 The scFv receptormodified T-cell population, for all transductions, consisted of Z85% CD8 þ cells, as demonstrated previously. 15, 16, 22, 23 Antigen-specific binding, cytotoxicity and cytokine secretion by scFv-modified T cells
The ability of transduced mouse T lymphocytes to bind specifically to tumor cells was determined in a rosetting assay as described. 20 The cytolytic capacity of transduced T cells was determined in a 6-hour 51 Cr-release assay as described.
14 The ability of scFv-modified mouse T cells to secrete cytokine after erbB2 antigen ligation was determined by enzyme-linked immunosorbent assay (ELISA) (PharMingen). Briefly, gene-modified mouse T lymphocytes (10 6 ) (transduced with LXSN plus scFv-anti-erbB2-CD28-z, mutant receptors scFv-anti-erbB2-CD28-(P187/ 190A)-z and scFv-anti-erbB2-CD28-(Y170F)-z or mocktransduced T cells) were cocultured with MC38-erbB2 or MC38 (10 6 ) tumor cells in 12-well plates for 20 hours. No exogenous IL-2 was added. Supernatants were harvested and IFN-g, IL-2, GM-CSF, TNFa and IL-4 production by transduced T cells was determined by ELISA. Cytokine production through stimulation of endogenous CD3 and CD28 receptors was assessed for each T-effector cell population using plate-bound CD3 (1 mg/ml) (145.2C11; PharMingen) and CD28 (1 mg/ml) (37.51; PharMingen) mAbs.
Proliferation assays
Gene-engineered mouse T lymphocytes (10 5 cells/well) were cultured in 96-well U-bottom plates media alone, cocultured with irradiated MC-38-erbB2 or MC-38 tumor cells (10 5 
Results
Expression of wild-type and mutant scFv receptors in primary mouse T cells
Several chimeric receptor gene constructs were engineered in mouse T cells, composed of the scFv (variable heavy chain (V H ) and V L ) regions of the anti-erbB2 mAb linked via a CD8 hinge to the transmembrane and cytoplasmic regions of CD28, CD28-(P187/190A) or CD28-(Y170F) fused to the intracellular domain of z (Fig 1a) . High and equivalent levels of cell surface receptor expression on T cells retrovirally transduced with wild-type scFv-a-erbB2-CD28-z and mutant (scFv-CD28-(P187/190A)-z and scFv-CD28-(Y170F)-z) receptors were demonstrated by flow cytometry following staining with an anti-c-myc tag mAb (Fig 1b-d) . Binding of the anti-c-myc tag antibody was specific for cells transduced with scFv constructs since receptor expression could not be detected on T cells transduced with the pLXSN retroviral vector alone (Fig  1e) . Consistent with our previous data, the transduced Tcell populations consisted predominantly of CD8 þ cells (Z85%). 15, 16, 22, 23 Antigen-specific binding and cytotoxicity of wild-type and mutant scFv receptors in primary mouse T cells T lymphocytes expressing the wild-type scFv-a-erbB2-CD28-z receptor or mutant scFv receptors, scFv-CD28-(P187/190A)-z or scFv-CD28-(Y170F)-z, were demonstrated to conjugate equivalently and specifically with the erbB2 þ human melanoma cell line MEL 624.38 (wild type, 30.270.8% versus P187/190A, 34.370.9% versus Y170F, 31.270.8%, n ¼ 3) but not the erbB2 À sarcoma cell line 24JK (wild-type, 0.670.4% versus P187/190A, 0.670.6% versus Y170F, 0.370.3%, n ¼ 2). In contrast, T cells transduced with the pLXSN retroviral vector alone demonstrated no specific binding to MEL 624.38 (0.570.3%, n ¼ 3) or 24JK tumor targets (0.370.3%, n ¼ 2). We next examined whether incorporation of the P187/190A or Y170F mutations into the CD28 signaling domain of the scFv-CD28-z receptor affected antigenspecific cytolysis in a 6-hour 51 Cr release assay. The cytolytic capacity of T cells expressing either the wild-type or mutant scFv receptors was shown to be equivalent against MC38-erbB2 tumor cells, and demonstrated antigen-specific killing of approximately 35-40% at an E:T ratio of 40:1 (Fig 2a) . Lysis was antigen-specific since transduced T cells were unable to lyse erbB2
À parental MC38 cells and T cells transduced with the LSXN vector alone were unable to lyse either MC38-erbB2 or MC38 tumor cells (Fig 2b) . These data indicated that the incorporation of the P187/190A or Y170F receptor mutations within the CD28 cytoplasmic tail did not affect antigen-specific binding or cytotoxicity of engineered T cells. The lack of involvement of CD28 in cytolytic activity is consistent with our previous data that demonstrated that T cells engineered with an scFv-CD28 chimera were unable to lyse antigen-expressing tumor cells. 22 In addition, lysis by scFv-CD28-z-expressing T cells was equivalent to T cells expressing the scFv-z chimera as shown previously. 22 
Reduced cytokine secretion by mouse T lymphocytes expressing mutant scFv receptors
We have previously demonstrated enhanced IFN-g and GM-CSF secretion after specific antigen ligation by primary mouse T cells expressing an scFv-CD28-z receptor containing both mouse CD28 and human 
TCR-z cytoplasmic signaling domains compared to T cells expressing an scFv receptor containing the TCR-z signaling domain alone (scFv-z). 23 Thus, it was of interest to compare the ability of primary mouse T cells expressing the wild-type scFv-a-erbB2-CD28-z receptor or mutant scFv receptors, scFv-CD28-(P187/190A)-z or scFv-CD28-(Y170F)-z containing the mouse TCR-z signaling domain, to secrete IFN-g and GM-CSF following erbB2 antigen ligation. The results demonstrated similar high-level secretion of both IFN-g and GM-CSF by the scFv-CD28-z wild-type receptor (1220752 and 68724 pg/ml, respectively), as previously observed, 23 which, for IFN-g, was equivalent to stimulation through the endogenous TCR and CD28 receptors (Fig 3a,b) . In contrast, T cells expressing either the P187/190A or Y170F scFv mutant receptors demonstrated a significant reduction in IFN-g secretion (66372 and 37722 pg/ml, respectively) and no detectable secretion of GM-CSF. As previously demonstrated, T cells engineered with the scFv-z chimera produced low levels of IFN-g (o250 pg/ml) and negligible secretion of GM-CSF. Mock-transduced T cells did not secrete detectable IFN-g or GM-CSF (Fig 3a,b) . Importantly, only background levels of either IFN-g or GM-CSF were detected following incubation of T cells expressing the wild-type scFv receptor, mutant scFv receptors or pLXSN vector alone with erbB2 À MC38 target cells (Fig 3a,b) . The capacity of these gene-modified T cells to secrete other cytokines (IL-2, TNF-a, IL-4) after specific ligation of MC38-erbB2 tumor cells was also compared. There was no detection of IL-2, TNF-a or IL-4 by either wild-type or mutant scFv receptors (data not shown). The reduced secretion of IFN-g and GM-CSF by mutant scFv receptors suggested a critical signaling role for CD28 within the scFv chimeric receptor.
Reduced proliferation by primary mouse T cells expressing mutant scFv receptors
Previous studies have demonstrated increased proliferation of T cells expressing the scFv-CD28-z receptor when compared to T cells expressing the scFv-z receptor. 23 Thus, it was of interest to assess the ability of primary mouse T cells expressing the wild-type scFv-a-erbB2-CD28-z receptor or mutant scFv receptors, scFv-CD28-(P187/190A)-z or scFv-CD28-(Y170F)-z, containing the mouse TCR-z signaling tail, to trigger a proliferative response in a [
3 H]thymidine incorporation assay after specific ligation with irradiated MC38-erbB2 tumor targets. Consistent with previous studies, T cells expressing the wild-type scFv-CD28-z receptor demonstrated a high proliferative capacity (2072572931 cpm) compared to T cells expressing the scFv-z chimera (50237194 cpm), 23 and proliferation by T-scFv-CD28-z cells was similar to that observed for T cells stimulated through the endogenous TCR and CD28 receptors. In contrast, T cells expressing either the P187/190A or Y170F scFv mutant receptors demonstrated a marked reduction in proliferation (351272361 and 392571972 cpm, respectively), while mock-transduced T cells did not proliferate in response to either antigennegative or -positive tumor targets (Fig 4) . Importantly, T cells expressing the wild-type scFv receptor, mutant scFv receptors or pLXSN vector alone did not proliferate when incubated with irradiated erbB2 À MC38 cells (Fig 4) . Together with the significant reduction observed for cytokine release, the marked decrease in proliferation observed for both scFv mutant receptors after erbB2 antigen ligation indicated an important costimulatory role for CD28 within the scFv-CD28-z receptor.
Primary mouse T cells expressing mutant scFv receptors demonstrate decreased antitumor efficacy after adoptive transfer
Although we were able to demonstrate reduced signaling function by mutant scFv receptors in vitro, we next Cytokine production by wild-type and mutant scFv receptors was statistically compared by a Mann-Whitney U-test (*Po.0001).
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wanted to determine whether T lymphocytes expressing mutant scFv receptors had reduced antitumor efficacy in vivo after adoptive transfer. To test this, transduced T cells expressing the wild-type scFv-a-erbB2-CD28-z receptor or mutant scFv receptors, scFv-CD28-(P187/ 190A)-z or scFv-CD28-(Y170F)-z, were transferred intravenously into BALB/c RAG-1 À/À mice bearing subcutaneous MC38-erbB2 tumors. Mouse T lymphocytes expressing the wild-type scFv-a-erbB2-CD28-z receptor eradicated tumors in seven of 10 mice. As previously shown, this was a significant improvement in the number of tumors eradicated compared with mice receiving T cells engineered with the scFv-z chimera (three out of 10 tumors eradicated). 23 Interestingly, T lymphocytes expressing either the scFv-CD28-(P187/190A)-z or scFv-CD28-(Y170F)-z mutant receptors were much less effective in inhibiting tumor growth than T lymphocytes expressing the wild-type scFv receptor. No tumor eradication was observed in mice receiving T lymphocytes expressing the scFv-CD28-(P187/190A)-z receptor mutation and only one out of 10 tumors was eradicated in mice receiving T lymphocytes expressing the scFv-CD28-(Y170F)-z receptor (Fig 5) . Tumor eradication by T lymphocytes expressing the wild-type scFv-a-erbB2-CD28-z receptor was antigen-specific since tumor growth was not effected in mice treated with mocktransduced T lymphocytes (Fig 5) . Overall, these results conclusively demonstrated a critical functional role for the CD28 cytoplasmic component of the scFv-CD28-z receptor in stimulating the activity of T cells both in vitro and in vivo.
Discussion
Recent developments in the design of scFv chimeric receptors, containing both primary TCR-z and costimulatory CD28 signaling domains, have shown tremendous promise for adoptive cancer immunotherapy. [22] [23] [24] [25] Nevertheless, none of these studies have formally demonstrated whether CD28 makes a contribution to the function of these chimeras or whether the incorporation of CD28 into the scFv receptor simply acts as a spacer to enhance the function of the TCR-z component in gene-engineered T cells. In this study, we have made a significant advance in the investigation of the function of scFv-CD28-z receptors by clearly demonstrating a role for the cytoplasmic CD28 component when placed in tandem with the TCR-z domain (Fig 6a-c) . We have determined, through mutational analysis, that specific signaling motifs within the CD28 component of the scFv-CD28-z receptor enhanced the proliferation and cytokine secretion of engineered T cells in vitro and the antitumor efficacy of engineered T cells in vivo, thus eliminating the probability that CD28 acts simply as a spacer domain. T cells expressing either scFv-CD28-(P187/190A)-z or scFv-CD28-(Y170F)-z receptors, carrying mutations within the PXXP or YMNM cytoplasmic CD28 signaling motifs, respectively, demonstrated a reduced ability to proliferate and produce IFN-g and GM-CSF following antigen ligation in vitro (Fig 6b,c) and a decreased capacity to eradicate tumor in vivo compared to T cells expressing the wild-type scFv-CD28-z receptor. Importantly, the incorporation of either P187/190A or Y170F mutations within the CD28 cytoplasmic domain did not affect cell surface receptor expression or the ability of gene-engineered T cells to bind specifically to or lyse antigen-expressing tumor targets in vitro. This result was consistent with the fact that no cytolytic function has been associated with CD28 signal transduction and that TCR-z alone can support antigen-dependent cytotoxicity. 16, 22, 24 The results also suggested that any conformational change possibly occurring from mutation of either the proline or tyrosine residues within the CD28 signaling tail did not compromise the binding capacity of the extracellular a-erbB2 scFv component with cognate antigen or affect the cytolytic function of the TCR-z chain after antigen ligation.
A number of studies have investigated the effect of P187/190A or Y170F mutations on signal transduction of the endogenous CD28 receptor in T cell lines and primary mouse T cells. In general, these studies have been conflicting and the exact biochemical events associated with TCR-z and CD28 signal processing leading to important biological parameters such as proliferation and cytokine release remain to be clarified. [28] [29] [30] Nevertheless, some studies have revealed that CD28 proline residues 187 and 190, contained within the cytoplasmic PXXP signaling motif, interact with and activate the tyrosine kinase Lck, thereby providing maximal costimulation of T cells. 28 In our study, we were unable to detect reliably any changes in Lck activity between mock-or scFv-transduced T cells after receptor triggering through either immobilized anti-CD3/anti-CD28 mAb's or antitag mAb (data not shown). These experiments were compromised by the fact that cycling T cells (after PHA and IL-2 stimulation) display some background level of kinase activity. Holdorf et al 28 also demonstrated that the P187/190A mutation of the endogenous CD28 receptor caused a loss in T-cell proliferation in both transformed and primary mouse T cells. Our data were consistent with these findings in that primary mouse T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor demonstrated a significant decrease in proliferative capacity when compared to T cells expressing the wild-type scFv-CD28-z receptor, supporting a specific role for CD28 proline residues 187 and 190 in T-cell proliferation. Although the effect of endogenous CD28 P187/190A mutations on cytokine secretion in mouse T cells has not been reported, we detected a significant decrease in both IFN-g and GM-CSF production in T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor compared to T cells expressing the wild-type scFv-CD28-z receptor. Taken together, the reduction in proliferation and cytokine secretion by T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor clearly indicated a functional role for the CD28 component of the receptor in signal transduction (Fig 6b) . Interestingly, we demonstrated a complete inability of T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor to eradicate erbB2 þ tumor in BALB/c RAG-1 À/À mice, compared with T cells expressing the wild-type scFv-CD28-z receptor that eradicated seven of 10 tumors. Given that we have previously demonstrated a critical role for IFN-g in vivo for scFv-CD28-z-engineered T cells, 23 the reduced secretion of IFN-g by T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor in vitro and reduced antitumor efficacy in vivo highlights the importance of IFN-g as an effector molecule used by T cells expressing the scFv-CD28-z chimera.
In addition to studies investigating the effect of CD28 receptor P187/190A mutations on T-cell function, other reports have demonstrated that phosphorylation of tyrosine residue 170 of the YMNM motif within the cytoplasmic domain of CD28 is critical for binding and activation of phosphatidylinositol 3-kinase (PI3 kinase). 26, 27, 31 Nevertheless, the signaling events associated with the YMNM motif in CD28 costimulation remain controversial, and we did not detect any changes in PI3 kinase activity between mock-transduced or scFv-expressing T cells (data not shown). Several groups have investigated the effect of the CD28 Y170F mutation on cytokine secretion. An early study suggested a role for the YMNM motif in cytokine secretion by reporting abrogation of IL-2 secretion in mouse T-cell hybridomas containing the Y170F mutation of the endogenous CD28 receptor. 26, 32 In contrast to this study, Truitt et al 33 reported no effect on IL-2 secretion by the same mutation in the Jurkat T-cell leukemic line. These discrepancies were thought to be a result of the different cells used in these studies, although the role of the YMNM motif failed to be resolved in more recent studies A role for costimulation by engineered T cells M Moeller et al using transgenic mice. Harada et al 29 reported that T cells expressing the CD28 Y170F mutation were defective in IL-2 production, while Okkenhaug et al 30 reported the Y170F mutant CD28 to be indistinguishable from wildtype CD28 in mediating IL-2 production. Despite these studies, our results have demonstrated a functional role for the YMNM motif of CD28 in mediating proliferation and cytokine secretion of gene-engineered T cells in vitro (Fig 6c) and demonstrated the YMNM motif to be important for enhanced antitumor efficacy of engineered T cells in vivo. It is important to note that our geneengineered T cells expressing either wild-type or mutant scFv receptors secreted minimal levels of IL-2, even after stimulation through endogenous TCR and CD28 receptors, as previously demonstrated. 23 Our transduced mouse T-cell population consisted mainly of CD8 þ cells that produce negligible levels of IL-2 compared with mouse CD4 þ T cells. 34 Interestingly, the reduction in IFN-g secretion by T cells expressing the scFv-CD28-(Y170F)-z receptor was significantly greater than for T cells expressing the scFv-CD28-(P187/190A)-z mutant receptor, suggesting that the tyrosine residue 170 of CD28 plays a more critical role in cytokine secretion, particularly IFN-g, for scFv-CD28-z-engineered T cells.
Overall, our data provided insight into the function of scFv chimeric receptors, which combine in tandem TCR-z and CD28. Tumor-reactive T cells engrafted with the scFv-CD28-z receptor effectively integrate receptormediated TCR-z and CD28 signaling pathways, enabling engineered T cells to mimic the dual-signal model of T-cell activation necessary for induction of important T-cell activation functions in vivo including cytokine secretion and proliferation. A single receptor construct incorporating both CD28 and TCR-z signaling domains bypasses problems associated with expressing multiple receptors in primary T cells. Further understanding and optimization of the signaling capacity of scFv chimeric receptors will aid in translation of the T-cell chimeric receptor approach into the clinic and establish a functional receptor that can be used as a platform for the generation of receptors incorporating other novel costimulatory domains.
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